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Summary Beginning in 1975, 78 patients with resected stage B and C colorectal carcinoma were randomly
assigned (2:1) to receive either levamisole 2.5 mgkg' day given for 2 days every week for 18 months or
placebo therapy in the same schedule. Pretreatment characteristics (age, gender, disease site, CEA and stage)
and the pattern of follow-up were similar in both groups. For the first 5 years following randomisation,
relapse-free survival and overall survival were similar in the two treatment groups. Subsequently, excess late
mortality was associated with levamisole group assignment. Consequently, overall survival was somewhat
greater in the placebo group than in the levamisole group, 68% vs 38% (P <0.08). For patients surviving 5
years from randomisation, subsequent survival favoured placebo over levamisole (100% vs 57%; P <0.03).
The absolute numbers of deaths were 27 in the levamisole group (19 definitely cancer related) and seven in the
group placebo (five definitely cancer related). This long-term result seen with a more intensive adjuvant
levamisole dose and schedule suggests: (1) other levamisole adjuvant trials in patients with colorectal cancer
should be examined for long-term outcome; (2) future trials utilising the even higher levamisole dosage
required for clinical immunomodulation should proceed cautiously.
The initial suggestion of potential benefit for levamisole as
adjuvant therapy in colorectal cancer management came
from a trial by Verhaegen and colleagues (Verhaegen, 1978;
Verhaegen et al., 1982) initiated in 1974. A series of subse-
quent studies of levamisole in this disease as sole surgical
adjuvant have produced less consistent results (Bancewicz et
al., 1980; Chlebowski et al., 1982; Sertoli et al., 1987; Arnaud
et al., 1989).
More recently, in trials using combined 5-fluorouracil (5-
FU) and levamisole as adjuvant therapy for patients with
resected colon cancer more favourable results have been
reported. Windle et al. (1989) observed survival benefit of
short-course levamisole therapy when combined with 5-FU
as compared with 5-FU alone or no adjuvant. In two larger
trials, substantial reduction in rate of disease recurrence and
patient death on a longer duration levamisole-5-FU com-
bination were reported (Laurie et al., 1989; Moertel et al.,
1990). These results, together with a 'Clinical Alert' from the
National Cancer Institute (United States), have led to rapid
acceptance of levamisole and 5-FU as standard adjuvant
therapy for this disease in the USA, but not universally
(National Cancer Institute, 1990; Moertel, 1992). Against this
background, the long-term follow-up of one of the earliest of
the levamisole studies, initiated by the Western Cancer Study
Group (WCSG) in 1975, is now reported.
Materials and methods
Eligibility
Details of the patient eligibility and study design have been
previously reported (Chlebowski et al., 1988). Briefly, all
patients had histologically proven, stage B or C carcinoma of
the colon or rectum. No prior chemotherapy or immuno-
therapy was permitted. Patients were less than 75 years old
with Karnofsky performance status >60%. Written in-
formed consent meeting all federal and institutional
requirements was obtained. A CEA level < 10.0 ng ml-'
obtained 2 weeks following definitive surgery was required.
Intraoperative needle biopsy of both liver lobes was strongly
recommended. However, if preoperative liver function abnor-
malities were present, then biopsy of the liver was required
for eligibility with results free of malignancy. All patients
were required to have normal renal function and no evidence
of metastatic disease on baseline chest radiograph and liver
scan and baseline total WBC of >4,000. Entry on study
within 45 days of primary surgery was also required.
Treatment plan
After confirmation of eligibility, patients were randomly
assigned by telephone contact with the Western Cancer Study
Group Statistical Center to either placebo or levamisole using
a random number generation system. Stratification was based
on primary disease site (colon or rectum) and pathological
stage (Dukes' B or C). Randomisation was weighed two to
one in favour of levamisole entry. Levamisole was obtained
from Jansen Pharmaceuticals (NJ, USA) in 50 mg tablets.
Levamisole dosage was 2.5 mg kg-' day-' in three divided
doses taken on days 1 and 2. Days 3-7 were rest days (no
levamisole), with a new treatment cycle begun weekly. Treat-
ment was continued for 18 months or until disease recur-
rence. Placebo pills, identical to levamisole in appearance,
were administered on the same schedule. Patients developing
significant nausea, skin rash or mylosuppression had medica-
tion held per protocol until resolution of symptoms. Therapy
was then reinitiated with a 50% dose reduction with poten-
tial for escalation back to full dose.
Clinicalfollow-up
Follow-up studies during the initial 18 months after entry
included: chest radiograph; liver function tests and liver scan
every 16 weeks; and CEA every 8 weeks. Subsequently, all
these studies were performed every 6 months or as clinically
indicated.
In response to a request to include data from this trial in
an upcoming Overview Analysis of the Colorectal Cancer
Collaborative Group, follow-up of this patient group was
conducted in mid-1993. A concerted effort was made to
obtain information on the current status of all entered
patients by contacting originally participating investigators,
institutional tumour registries, individual participants and
regional death registries.
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Statistical analysis
The initial target sample size, set in 1975 following then
current WCSG procedures, was 160 patients to be accrued
over 3 years. This accrual was not reached because of early
funding termination of the study group. The most recent
analysis of this protocol was performed in 1987 and pub-
lished in 1988 (Chlebowski et al., 1988).
Overall survival and relapse-free survival represent primary
study end points. Cause of death was pursued in all cases
and recorded when available. The survival curves were
generated using the Kaplan-Meier method with statistical
significance between treatments explored using the Mantel-
Cox method (Breslow, 1970). Randomised patients were
included in all analyses regardless of therapy received with all
analyses based on 'intent to treat'. Two-sided tests of stati-
stical significance were used.
Results
Between November 1975 and December 1978, 78 eligible
patients were randomised at seven participating clinical sites
to receieve either placebo or levamisole. Two patients, one on
each arm, did not receive drug. Pretreatment characteristics
were similar in the two groups (Table I).
Toxicity of levamisole was generally mild with moderate
nausea seen in 14%, stomatitis in 6% and dermatitis in only
4% of patients. One patient experienced agranulocytosis and
a therapy-related death on levamisole. No evidence for
neurological events attributable to levamisole was
documented.
As expected for a study with long-term follow-up, the
relapse-free survival results closely paralleled those based on
overall survival. The interval from relapse to death was
547 ± 148 days in the placebo vs 438 ± 143 days (mean +
s.e.m.) in the levamisole groups (not significant). Considering
all participants, overall survival for patients with Dukes' B
lesions exceeded those with Dukes' C lesions with 5 year
survival rates of 78% and 46% respectively (P <0.001).
The overall survival of all patients, by randomised treat-
ment group, is depicted in Figure 1. As seen, survival for
placebo- and levamisole-treated patients was similar for the
first 5 years. However, mortality after this period has only
been associated with levamisole group assignment. For the
entire study period, the trend favouring longer survival for
resected colorectal cancer patients on placebo over levamisole
therapy (68% vs 38% survival) approached statistical signifi-
cance (P <0.08). As expected for a trial with a relatively
modest number of events, 95% confidence intervals for
patient group survival were large (86-49% survival for
placebo and 51-25% survival for levamisole). For patients
surviving 5 years from entry, the chance of subsequent sur-
Table I Pretreatment patient characteristics
Placebo Levamisole
Number entered 24 54
Age, (years)
Mean (± s.e.m.) 60.1 ± 2.5 58.7 ± 1.8
Median 63.0 62.0
Sex
Male 14 25
Female 10 29
Site of disease
Colon 20 46
Rectum 4 8
Stage of disease
Dukes' B 11 25
Dukes' C 13 29
Preoperative CEA
Mean (± s.e.m.) 5.1 ± 1.3 7.9 ± 3.1
Median 3.5 2.6
vival was significantly greater for patients in the placebo
group (100%) than in the levamisole (57%) group
(P <0.03).
The absolute number of deaths and the pattern of patient
follow-up on each treatment arm are outlined in Tables II
and III. As seen, success in determining follow-up status was
similar for placebo and levamisole groups. Cause of death
was determined to be definitely cancer related in five of seven
placebo patients and 19 of 27 levamisole patients. One death
was directly related to levamisole toxicity, one death was
definitely not cancer related, and in the remaining deaths
information available did not permit unequivocal determina-
tion of cause. Survival results calculated on the basis of
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Figure 1 Overall patient survival by allocated treatment compar-
ing 54 levamisole-treated patients with 24 placebo-treated patients
(P <0.08).
Table II Summary: overall patient outcome and pattern of
follow-up
Proportion
Patient status of patients
Group Patients at last contact alive at
treatment randomised Dead Alive last contact
Placebo 24 7 17 0.7083
Levamisole 54 27 27 0.5000
Totals 78 34 44
Test statistic [generalised Savage (Mantel-Cox)] = 3.112;
P = 0.0777.
Table III Pattern of follow-up for patients alive at last contact by
treatment group
Date last Treatment group
contacted Placebo Levamisole
1975 0 1
1980 0 1
1981 1 1
1982 1 1
1983 0 4
1984 1 0
1985 6 2
1987 0 1
1988 1 0
1990 0 1
1991 1 1
1992 1 2
1993 5 11
17 27
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considering only deaths unequivocally cancer related also
favour placebo over levamisole (76% vs 51% survival), but
the difference was not significant. Deaths not definitely attri-
butable to cancer occurred throughout the long observation
period on the levamisole arm (at 21, 179, 1475, 1533, 2027,
2649, 4197 and 6071 days after randomisation).
The outcome for the 65 patients with colon cancer was
similar to that of the entire study population. Initially, sur-
vival of colon cancer patients receiving placebo or levamisole
was similar, but at 10 years survival was 72% on placebo vs
42% on levamisole in this group (P <0.08).
Discussion
Long-term follow-up of one of the earliest randomised trials
designed to compare levamisole with placebo therapy in
patients with resected colorectal cancer suggests that excess
late mortality may be associated with levamisole administra-
tion. This Western Cancer Study Group (WCSG) trial differs
from the two largest levamisole adjuvant studies in colorectal
cancer (Laurie et al., 1989; Moertel et al., 1990) by its higher
levamisole dose, absence of 5-FU, use of placebo and longer
duration of patient follow-up. The dose and schedule of
levamisole in this WCSG trial was more intensive than that
used in the studies involving 5-FU and levamisole from the
North Central Oncology Group (Laurie et al., 1989) and
InterGroup (Moertel et al., 1990) trials (Table IV). As seen,
the cumulative levamisole dose was more than two times
greater in the Western Cancer Study Group trial than that
used in the trials defining standard therapy regimens in the
USA. Although levamisole dose intensity may be related to
study outcome seen in the current report, even higher
levamisole dosage has been required to demonstrate clinical
immune modulation (Stevenson et al., 1991; Janik et al.,
1993), and future clinical trials with levamisole dose intensity
greater than the WCSG schedule have been recommended.
An unexpected number of late deaths were identified when
patients who had received levamisole were under long-term
observation for a study which now has more than 15 years'
median follow-up. As the North Central and InterGroup
trials in the USA were reported after 7.9 and 3 years' follow-
up respectively, additional follow-up of those studies will be
required to determine how levamisole group assignment, with
or without 5-FU, influences long-term survival.
No consistent cause of death in the levamisole group could
be attributed to toxicity. Agranulocytosis resulted in one
levamisole-associated patient death, but no other problems
related to myelosuppression have been identified in patients
given levamisole. Similarly, although multifocal inflammatory
leucoencephalopathy has been reported with adjuvant
levamisole regimens which include 5-FU (Hook et al., 1992),
neurological symptoms were not reported by our patients
receiving levamisole. Finally, Anthony et al. (1979) reported
a substantially increased number of deaths from cardiores-
piratory failure in a randomised trial involving perioperative
levamisole administration in patients with localised lung
cancer, with mortality mostly occurring within 6 weeks of
levamisole use. In the current report, mortality in the
levamisole group occurred throughout the observation
period.
In many respects, the results of this trial are in agreement
with other reports. The similar survival for patients receiving
placebo and levamisole in the first 5 years as well as the
Table IV Comparative levamisole dose and schedule
Cumulative
Investigationa Levamisole doseandschedule dose (mg)b
WCSG Levamisole 2.5 mg kg-' day-' 23,400
(current study) given p.o. t.i.d. ondays 1 and 2
everyweek for 18 months
NCCTGand Levamisole 50 mg t.i.d. given 11,700
InterGroup p.o. for 3 daysevery 2 weeks
for 1 year
'WCSG, Western Cancer Study Group; NCCTG, Northern Central
Cancer Treatment Group; InterGroup, InterGroup study with
participation by NCCTG, the Eastern Cooperative Oncology Group
and the Southwest Oncology Group. bFor a 60 kg patient.
magnitude for patients with Dukes' B and Dukes' C disease
are quite similar to other cooperative group randomised
trials (Laurie et al., 1989; Moertel et al., 1990). In addition,
the infrequency of cancer-related deaths after 5 years and the
low risk of long-term deaths from any cause in the placebo
arm of this trial are as expected for a non-elderly population
of patients treated for localised colorectal cancer. However,
the continuing mortality seen in patients given levamisole
and followed for an extensive period represents an unantici-
pated study result. Although other explanations for these
observations, including the play of chance in a small sample,
must be considered, attention to these results for hypothesis
generation is warranted, since clinically effective alternatives
to levamisole therapy are available for adjuvant therapy in
this disease (O'Connell et al., 1993; Wolmark et al., 1993;
Zaniboni et al., 1993).
The negative results associated with non-specific immune
modulation approaches which have been reported in breast
cancer trials also suggest that long-term assessment of
levamisole adjuvant results in colorectal cancer may be pru-
dent. Using dosage similar to that used in the current study,
levamisole shortened response and survival in chemotherapy-
maintained advanced breast cancer patients (Samal et al.,
1984). As adjuvant, non-specific immune modulation with
levamisole or BCG has resulted in either inconsistent (Danish
Breast Cancer Group, 1980; Treuniet-Donber et al., 1987) or
negative influence (Danish Breast Cancer Group, 1980; Early
Breast Cancer Trialist Group, 1992) on breast cancer patient
outcome when long-term follow-up has been completed.
In summary, after over 15 years of follow-up, unexpected
late mortality was associated with levamisole group assign-
ment in a randomised, placebo-controlled adjuvant trial in
patients with resected colorectal cancer. We conclude: (1)
other adjuvant trials in this disease which include levamisole
treatment should be explored for long-term survival outcome;
and (2) levamisole trials recommending higher dosage with-
out strong preclinical support should proceed with caution.
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